Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab

Evobrutinib shows promise in treatment of multiple sclerosis

21 Aug 2019

Daily use of the selective oral Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.

A total of 267 patients were randomly assigned to one of the following treatment groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference.

The primary endpoint of mean total (cumulative) number of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12 through 24 was 3.85 in the placebo group, 4.06 in the evobrutinib 25-mg group, 1.69 in the 75-mg once-daily group, 1.15 in the 75-mg twice-daily group and 4.78 in the DMF group.

Compared with placebo, evobrutinib 75-mg once-daily significantly reduced the reduced the number of lesions over time (adjusted rate ratio, 0.30; p=0.005). The difference noted between placebo and the 25-mg group (adjusted rate ratio, 1.45; p=0.32) or the 75-mg twice-daily group (adjusted rate ratio, 0.44; p=0.06) was not significant.

Annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group. Scores on the Expanded Disability Status Scale (EDSS) did not significantly change from baseline across all treatment groups.

There were elevations in liver aminotransferase values observed with evobrutinib.

The researchers acknowledged the need for longer and larger trials to establish the risk­–benefit profile of the drug.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab